Deepshikha started her career in orthopedic device marketing in Japan. Thereafter she transitioned to marketing cardiovascular devices and subsequently moved to the US to lead regulatory teams in developing and implementing global regulatory strategies for cardiovascular/endovascular stents, Companion Diagnostic assays, Digital health solutions and NGS tests. At GRAIL her focus is on delivering on the mission – Finding Cancer Early, When it can Be Cured.
Prior to joining Thrive, she was vice president, head of public policy for Foundation Medicine, where she was responsible for developing, advocating and executing company positions before Congress and the U.S. Food and Drug Administration (FDA), including the landmark parallel review decision by the FDA and Centers for Medicare and Medicaid Services (CMS) on next generation sequencing for Foundation Medicine’s flagship product. Before that, she spent time outside of the industry, as senior counsel to Senator Arlen Specter, where she was lead policy and strategic advisor for issues related to tax, banking, healthcare and finance. Prior to that, she was lead counsel to the Senate Judiciary Committee, providing policy analysis and strategic counsel to both Chairman Specter and Republican and Democrat senators on the Committee.